MicroVention Announces New Sizes of Web System and 5-Year WEB-IT Trial Data

July 31, 2023—MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the addition of two sizes to its Web aneurysm embolization system. The Web system is now available in single-layer (SL) 6 X 2 mm and SL 7 X 2 mm sizes, which allow for the treatment of different sizes and shapes of aneurysms.

According to MicroVention, the Web device is an intrasaccular flow disruptor for the treatment of intracranial wide-neck bifurcation aneurysms, while sealing the neck and protecting the dome with the company’s MicroBraid technology.

The company is introducing the new devices and showcasing its product portfolio at SNIS 2023, the Society of NeuroInterventional Surgery’s 20th annual meeting held July 31 to August 4 in San Diego, California.

MicroVention also announced the publication of 5-year follow-up data from WEB-IT, the pivotal Web intrasaccular therapy study. The 5-year data were published by David J. Fiorella, MD, et al online in SNIS’s Journal of NeuroInterventional Surgery.

Dr. Fiorella and Adam Arthur, MD, are the Principal Investigators of the WEB-IT trial. Dr. Fiorella is Director of the Stony Brook Cerebrovascular Center, Co-Director of the Stony Brook Cerebrovascular and Comprehensive Stroke Center, and Professor of Neurosurgery and Radiology at Stony Brook Medicine in Stony Brook, New York. Dr. Arthur is James T Robertson Professor and Chair at The University of Tennessee Health Science Center in Memphis, Tennessee.

The WEB-IT trial supported FDA approval of the Web device, which the company announced in January 2019. The Web system received European CE Mark approval in 2010.

The company noted that the Web intrasaccular device has been evaluated in seven good clinical practice (GCP) studies and more than 200 peer-reviewed publications.

“From the GCP studies, there is currently a total of 1,464 patient-years and counting, from 601 patients, during which no patient has experienced bleeding or rebleeding from a Web-treated aneurysm—a remarkable track record of effectiveness over a large, accumulated experience,” commented Dr. Fiorella in MicroVention’s press release.

Dr. Arthur added, “It is great to have long-term follow up on this large, adjudicated GCP study. At this time, there is no device that has been shown to be safer for aneurysm patients than Web. So, if a patient with a wide-neck bifurcation aneurysm can be treated with Web, that ought to be the primary consideration.”